Shanghai, China – August 24, 2017 — Asieris Pharmaceuticals, a clinical stage biopharmaceutical company, announced today that the company has been invited to present at the 20th Annual Meeting of Chinese Society of Clinical Oncology (CSCO) being held on September 27-29th in Xiamen, China. Asieris is going to present the preliminary results of a phase II trial of APL-1202, an oral metaP2 inhibitor, in treating high-risk non-muscle invasive bladder cancer (NMIBC) patients relapsed from intravesical therapies.
Bladder cancer is the most common cancer type in the genitourinary tract system. In China, its annual incidence is over 80,000 patients, and has the 6th highest cancer incidence rate in men. NMIBC is the early stage of bladder cancer, and the standard of care is transurethral resection (TUR) followed by intravesical chemo or immunotherapies. High-risk NMIBC patients failed intravesical therapies need to take radical cystectomy. There have been no new drugs approved for this disease in nearly twenty years.
The theme of the 20th CSCO conference is“Together we innovate upon our heritage”. Adhering to CSCO’s mission, the conference provides great opportunities for worldwide informational exchange and collaboration in clinical oncology. The goal is to advocate standardization of comprehensive treatment, encourage innovation in clinical research, and promote the development of clinical oncology.